Agape Atp Corp SEC Filings

Agape ATP Corporation filed an amendment to its proxy materials for the upcoming Annual Meeting to clarify how abstentions and broker non-votes are treated and how certain proposals will be approved.

The revised language explains that broker non-votes arise when brokers lack discretionary authority and do not receive instructions, and confirms they are not counted as shares entitled to vote on non-routine matters. It also emphasizes that beneficial owners must give specific instructions if they want their street-name shares voted on non-routine items.

For Proposal 5, which seeks to amend the articles of incorporation to increase authorized common shares from 500,000,000 to 30,000,000,000, a majority of all voting shares must vote “FOR,” and abstentions and broker non-votes will count as “NO” votes. For Proposal 6, approval requires a majority of shares present and entitled to vote, abstentions count as votes against, and the item is considered routine, so broker non-votes are not expected.

Agape ATP Corporation is asking stockholders to approve several major corporate actions at its virtual annual meeting on January 30, 2026. Holders of 50,027,000 common shares as of November 4, 2025 can vote on ratifying Assentsure PAC as auditor, re-electing five directors, and authorizing potential issuances of common stock with an aggregate offering price of up to $300,000,000 under a future Form S-3 shelf. The company is also seeking authority for the board to implement one or more reverse stock splits of up to 1-for-5,000 and to increase authorized common shares from 500,000,000 to 30,000,000,000, which could significantly expand its ability to issue new equity. Another proposal would allow adjournment of the meeting to solicit more proxies if needed.

Agape ATP Corporation issued a press release on December 12, 2025 titled “Agape ATP Corporation Issues Statement on Recent Market Activity and Reaffirms Strategic Outlook.” The company furnished this press release as Exhibit 99.1 to a current report so readers can review its statement on recent market conditions and its reaffirmed strategic plans.

Agape ATP Corporation reported higher Q3 revenue and ongoing losses. For the quarter ended September 30, 2025, revenue was $370,593 versus $331,289 a year ago, while net loss was $(595,370). For the nine months, revenue reached $1,125,129 and net loss totaled $(1,931,535). Basic and diluted loss per share was $(0.01) for the quarter.

Total assets rose to $24.39 million as of September 30, 2025, driven by $23.83 million of prepayments and deposits, including a $23,000,000 deposit to Bi Cheng Investment Management Limited to identify and manage investment opportunities; the investment has yet to be identified. Cash and cash equivalents were $133,714. Total liabilities were $1.59 million, and total equity was $22.80 million.

The company issued 46,000,000 common shares in 2025, generating proceeds of $23,000,000. Shares outstanding were 50,027,000 as of November 10, 2025. Management disclosed “substantial doubt” about the ability to continue as a going concern due to losses, operating cash outflows of $2.21 million for the nine months, and uncertainty around the investment deposit.

Agape ATP Corporation (ATPC) reported interim results showing revenue growth but continuing losses and a material liquidity shift. Consolidated assets rose to $24.7 million from $3.24 million largely because the company remitted a $23.0 million deposit for an entrusted investment to Bi Cheng Investment Management Limited that remains unallocated as of the reporting date. Cash and cash equivalents fell to $215,973 from $2.04 million after that deposit and operating outflows.

Revenue for the six months was $754,536 (up from $631,682), but the company recorded a six-month net loss of $1,336,165 and used $1,948,332 in operating cash flow. Stockholders' equity rose to $23.41 million following issuance of 46,000,000 shares and proceeds of about $23.0 million, while the accumulated deficit widened to $10.83 million. Management disclosed substantial doubt about the company’s ability to continue as a going concern given the investment deposit is not yet deployed and operating losses persist.